Email alerts

Subscribe to our mailing list


Since Tri-Solfen® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW


Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Canada Humans Granted


Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.


Tri-Solfen® Wins ‘Best New Food Animal Product’

January 17, 2017

Animal Pharm Awards 2016: Companion animal innovation dominates as winners announced

By Joseph Harvey,   Published: 17 January 2017 03:13 PM

This year’s Animal Pharm Awards have highlighted the upsurge in innovation for companion animals that occurred in 2016…..

Best new food animal product winner – Animal Ethics

This year’s winner of best new food animal product is an anesthetic developed by Animal Ethics.

Although Tri-Solfen is only approved for use in Australia, the judging panel said the product has the potential to be a game-changer worldwide – it is the only topical anesthetic and antiseptic pain relief product approved for livestock anywhere in the world.

Tri-Solfen is the first product developed from Animal Ethics’ patented platform technology. The company believes the product has the potential to fill a large unmet need in the global marketplace for the management of accidental wounds and wounds caused by surgery in livestock and companion animals.

Tri-Solfen is a combination topical anesthetic and wound care agent, which is sprayed onto the wound to simultaneously anesthetize, alleviate pain, control bleeding and protect against infection. Its viscous gel base is also designed to form a long-lasting protective barrier over the wound.

The product was principally developed in Australia for use in sheep, to manage pain and bleeding associated with the invasive animal husbandry procedure mulesing. In Australia, the product has over 60% market penetration.

Animal Ethics said: “It has now proven to be highly successful in the treatment of accidental wounds, castration, tail docking, branding and disbudding in several species including cattle, pigs, sheep, goats and horses. Extensive trials in these livestock species has indicated that the onset of wound anesthesia is very rapid being readily apparent within one minute of application and there is evidence of a significant ongoing analgesic effect even after 24 hours.

“In addition, there is a clear reduction in blood loss and a statistically significant improvement in wound healing rates in treated versus untreated animals.”

Last year saw the further adoption of the product – over 70 million animals have been treated with Tri-Solfen since its original registration. In Australia the product is licensed to Bayer Animal Health.

While the product’s first Australian registration for the treatment of mulesing wounds was achieved in 2012, last year Tri-Solfen gained new product claims for lamb castration and tail docking. In December 2016, Australian regulatory authorities extended the use of Tri-Solfen to include the alleviation of pain in calves. These label extensions have contributed to an increase in the product’s sales this year.   READ FULL ARTICLE